. Significance: The diagnosis and treatment of prostate cancer (PCa) are limited by a lack of intraoperative information to accurately target tumors with needles for biopsy and brachytherapy. An innovative image-guidance technique using optical devices could improve the diagnostic yield of biopsy and efficacy of radiotherapy. Aim: To evaluate the performance of multimodal PCa detection using biomolecular features from in-situ Raman spectroscopy (RS) combined with image-based (radiomics) features from multiparametric magnetic resonance images (mpMRI). Approach: In a prospective pilot clinical study, 18 patients were recruited and underwent high-dose-rate brachytherapy. Multimodality image fusion (preoperative mpMRI with intraoperative transrectal ultrasound) combined with electromagnetic tracking was used to navigate an RS needle in the prostate prior to brachytherapy. This resulting dataset consisted of Raman spectra and co-located radiomics features from mpMRI. Feature selection was performed with the constraint that no more than 10 features were retained overall from a combination of inelastic scattering spectra and radiomics. These features were used to train support vector machine classifiers for PCa detection based on leave-one-patient-out cross-validation. Results: RS along with biopsy samples were acquired from 47 sites along the insertion trajectory of the fiber-optics needle: 26 were confirmed as benign or grade , and 21 as grade group , according to histopathological reports. The combination of the fingerprint region of the RS and radiomics showed an accuracy of 83% ( and a ), outperforming by more than 9% models trained with either spectroscopic or mpMRI data alone. An optimal number of features was identified between 6 and 8 features, which have good potential for discriminating grade group ( ) or grade group ( ). Conclusions: In-situ Raman spectroscopy combined with mpMRI radiomics features can lead to highly accurate PCa detection for improved in-vivo targeting of biopsy sample collection and radiotherapy seed placement.
Purpose: Spinal cord gray-matter imaging is valuable for a number of applications, but remains challenging. The purpose of this work was to compare various MRI protocols at 1.5 T, 3 T, and 7 T for visualizing the gray matter. Methods:In vivo data of the cervical spinal cord were collected from nine different imaging centers. Data processing consisted of automatically segmenting the spinal cord and its gray matter and co-registering back-to-back scans. We computed the SNR using two methods (SNR_single using a single scan and SNR_diff using the difference between back-to-back scans) and the white/gray matter contrast-to-noise ratio per unit time. Synthetic phantom data were generated to evaluate the metrics performance. Experienced radiologists qualitatively scored the images. We ran the same processing on an open-access multicenter data set of the spinal cord MRI (N = 267 participants).Results: Qualitative assessments indicated comparable image quality for 3T and 7T scans. Spatial resolution was higher at higher field strength, and image quality at 1.5 T was found to be moderate to low. The proposed quantitative metrics were found to be robust to underlying changes to the SNR and contrast; however, the SNR_single method lacked accuracy when there were excessive partial-volume effects. Conclusion:We propose quality assessment criteria and metrics for gray-matter visualization and apply them to different protocols. The proposed criteria and metrics, the analyzed protocols, and our open-source code can serve as a benchmark for future optimization of spinal cord gray-matter imaging protocols.
Objective: Multi-parametric magnetic resonance imaging (mpMRI) has become an important tool for the detection of clinically significant prostate cancer in the past two decades. Despite the high sensitivity of MRI for tissue characterization, it often suffers from a lack of specificity. Several well-established pre-processing tools are publicly available for improving image quality and removing both intra- and inter-patient variability in order to increase the diagnostic accuracy of prostate cancer. To date, most of these pre-processing tools have largely been assessed individually. In this study we present a systematic evaluation of a multi-step mpMRI pre-processing pipeline to automate tumor localization within the prostate using a previously trained model. Approach: The study was conducted on 31 treatment-naïve prostate cancer patients with a PI-RADS-compliant mpMRI examination. Multiple methods were compared for each pre-processing step: (1) bias field correction, (2) normalization, and (3) deformable multi-modal registration. Optimal parameter values were estimated for each step on the basis of relevant individual metrics. Tumor localization was then carried out via a model-based approach that takes both mpMRI and prior clinical knowledge features as input. A sequential optimization approach was adopted for determining the optimal parameters and techniques in each step of the pipeline. Main results: The application of bias field correction alone increased the accuracy of tumor localization (area under the curve (AUC)=0.77) over unprocessed data (AUC=0.74). Adding normalization to the pre-processing pipeline further improved diagnostic accuracy of the model to an AUC of 0.85. Multi-modal registration of ADC images to T2-weighted images improved the alignment of tumor locations in all but one patient, resulting in a slight decrease in accuracy (AUC=0.84). Significance: Overall, our findings suggest that the combined effect of multiple pre-processing steps with optimal values has the ability to improve the quantitative classification of prostate cancer using mpMRI. Clinical trials: NCT03378856 and NCT033677025
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.